Clinical Efficiency of Rituximab Combined with Autologous Hematopoietic Blood Stem Cell Transplantation for Treatment of CD20 / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 77-85, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-880035
ABSTRACT
METHODS@#From January 2005 to December 2013, 83 patients with refractory/recurrent CD20@*RESULTS@#All the patient achieved complete response. The median follow.up time was 39 months. Both the two groups collected peripheral blood stem cells successfully, and had no difference in hematopoietic reconstitution time. Three patients in treatment group and six patients in control group relapsed and the three year overall survival and EFS in treatment group was significantly higher than that in control group, that is(93.0% vs 73.1%, P=0.037) and (89.5% vs 65.4%, P=0.034), respectively. Subgroup analysis showed that compared with the treatment group in which using R in the whole courses(before and after transplantation, and collection of stem cells) was superior to the control group in both OS and EFS, with the OS 97% vs 87.5% (P>0.05) and EFS 97% vs 76.2% (P=0.05) respectively. While stratified by the different courses of rituximab, the OS was 88.9% (1-2 courses, 9 cases), 93.1% (3-4 courses, 29 cases), 94.7%(more than 5 courses,19 cases), and EFS was 77.8%, 89.7% and 94.7%, respectively.@*CONCLUSION@#For the patients with refractory/recurrent CD20
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Transplantation, Autologous
/
Lymphoma, Non-Hodgkin
/
Hodgkin Disease
/
Antineoplastic Combined Chemotherapy Protocols
/
Treatment Outcome
/
Hematopoietic Stem Cell Transplantation
/
Disease-Free Survival
/
Rituximab
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS